INVASIVE BREAST CARCINOMA
Clinical trials for INVASIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new INVASIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for INVASIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in shrinking aggressive breast tumors before surgery
Disease control CompletedThis study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (atezolizumab) given before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. 37 participants were …
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New drug combo shrinks tumors before surgery in early trial
Disease control CompletedThis early-phase study tested the safety and best dose of two drugs, abemaciclib and niraparib, given together before surgery to people with hormone receptor-positive, HER2-negative breast cancer. The goal was to see if this combination could shrink tumors before surgery. The tri…
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 16, 2026 23:36 UTC
-
New hope for tough breast cancer: drug combo shows promise in trial
Disease control CompletedThis study tested a drug called alisertib, either alone or with another drug called fulvestrant, in 96 postmenopausal women with advanced breast cancer that had stopped responding to hormone therapy. The goal was to see if these treatments could shrink tumors. While the approach …
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo shrinks hard-to-treat breast tumors before surgery
Disease control CompletedThis study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce…
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
9-Day radiation shows promise for breast cancer patients
Disease control CompletedThis study tested a shorter, 9-day course of whole breast radiation for people with early-stage breast cancer (stages 0 to IIB). The goal was to see if this condensed treatment is safe and effective, while also looking at cosmetic results and quality of life. A total of 102 parti…
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Cold sore virus engineered to attack breast cancer shows promise in early trial
Disease control CompletedThis study tested whether injecting a modified herpes virus (talimogene laherparepvec) directly into breast tumors, alongside standard chemotherapy before surgery, could destroy more cancer cells in people with triple negative breast cancer. The virus is designed to infect and br…
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New mammogram technique spots hidden breast cancers
Diagnosis CompletedThis study tested whether contrast-enhanced mammography (CEM) can find breast cancers that standard mammograms miss. 89 women already diagnosed or highly suspected of having breast cancer received CEM, which uses an iodine dye to make tumors stand out. The goal was to see if CEM …
Matched conditions: INVASIVE BREAST CARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Apr 26, 2026 20:02 UTC